Skip to main content

Research Repository

Advanced Search

A retrospective cohort study predicting and validating impact of the COVID-19 pandemic in individuals with chronic kidney disease

Dashtban, Ashkan; Mizani, Mehrdad A.; Denaxas, Spiros; Nitsch, Dorothea; Quint, Jennifer; Corbett, Richard; Mamza, Jil B.; Morris, Tamsin; Mamas, Mamas; Lawlor, Deborah A.; Khunti, Kamlesh; Consortium, CVD-COVID-UK; Sudlow, Cathie; Hemingway, Harry; Banerjee, Amitava

A retrospective cohort study predicting and validating impact of the COVID-19 pandemic in individuals with chronic kidney disease Thumbnail


Authors

Ashkan Dashtban

Mehrdad A. Mizani

Spiros Denaxas

Dorothea Nitsch

Jennifer Quint

Richard Corbett

Jil B. Mamza

Tamsin Morris

Deborah A. Lawlor

Kamlesh Khunti

CVD-COVID-UK Consortium

Cathie Sudlow

Harry Hemingway

Amitava Banerjee



Abstract

Chronic kidney disease (CKD) is associated with increased risk of baseline mortality and severe COVID-19, but analyses across CKD stages, and comorbidities are lacking. In prevalent and incident CKD, we investigated comorbidities, baseline risk, COVID-19 incidence, and predicted versus observed one-year excess death. In a national dataset (NHS Digital Trusted Research Environment [NHSD TRE]) for England encompassing 56 million individuals), we conducted a retrospective cohort study (March 2020 to March 2021) for prevalence of comorbidities by incident and prevalent CKD, SARS-CoV-2 infection and mortality. Baseline mortality risk, incidence and outcome of infection by comorbidities, controlling for age, sex and vaccination were assessed. Observed versus predicted one-year mortality at varying population infection rates and pandemic-related relative risks using our published model in pre-pandemic CKD cohorts (NHSD TRE and Clinical Practice Research Datalink [CPRD]) were compared. Among individuals with CKD (prevalent:1,934,585, incident:144,969), comorbidities were common (73.5% and 71.2% with one or more condition[s] in respective data sets, and 13.2% and 11.2% with three or more conditions, in prevalent and incident CKD), and associated with SARS-CoV-2 infection, particularly dialysis/transplantation (odds ratio 2.08, 95% confidence interval 2.04-2.13) and heart failure (1.73, 1.71-1.76), but not cancer (1.01, 1.01-1.04). One-year all-cause mortality varied by age, sex, multi-morbidity and CKD stage. Compared with 34,265 observed excess deaths, in the NHSD-TRE and CPRD databases respectively, we predicted 28,746 and 24,546 deaths (infection rates 10% and relative risks 3.0), and 23,754 and 20,283 deaths (observed infection rates 6.7% and relative risks 3.7). Thus, in this largest, national-level study, individuals with CKD have a high burden of comorbidities and multi-morbidity, and high risk of pre-pandemic and pandemic mortality. Hence, treatment of comorbidities, non-pharmaceutical measures, and vaccination are priorities for people with CKD and management of long-term conditions is important during and beyond the pandemic.

Journal Article Type Article
Acceptance Date May 9, 2022
Online Publication Date Jun 17, 2022
Publication Date 2022-09
Publicly Available Date May 30, 2023
Journal KIDNEY INTERNATIONAL
Print ISSN 0085-2538
Publisher Elsevier
Peer Reviewed Peer Reviewed
Volume 102
Issue 3
Pages 652-660
DOI https://doi.org/10.1016/j.kint.2022.05.015
Keywords chronic kidney disease; mortality; SARS-CoV-2
Publisher URL https://www.sciencedirect.com/science/article/pii/S0085253822004483?via%3Dihub

Files







You might also like



Downloadable Citations